Recent Updates
Recently added Catalysts
GERN Negative Sentiment Score: 30/100

GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is conducting an investigation into Geron Corporation on behalf of long-term stockholders due to a class action complaint. The complaint alleges that the company's board may have breached its fiduciary duties concerning the expectations for the launch and sales potential of its drug, Rytelo. Concerns are raised regarding the accuracy of information provided to investors, particularly the risks associated with the drug's commercialization and competition in the market.

Market Sentiment Analysis

CONCERNS & RISKS

  • Geron Corporation is under investigation for potential fiduciary breach.
  • A class action complaint has been filed against Geron, indicating significant legal risks.
  • The company faces scrutiny over misleading information related to the Rytelo drug's launch and growth expectations.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron (GERN) To Contact Him Directly To Discuss Their Options
If you are a long-term stockholder of Geron securities between February 28, 2024 and February 25, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigation concerns whether the board of directors of Geron have breached their fiduciary duties to the company.
The Complaint alleges that throughout the Class Period, Defendants provided investors with material information concerning Defendants' expectations for the launch and growth potential of Rytelo (imetelstat). The Complaint alleges that Defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug's sales.
If you are a long-term stockholder of Geron, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is Geron Corporation's stock symbol?

Geron Corporation's stock symbol is GERN.

Who can investors contact for more information?

Investors can contact Brandon Walker or Marion Passmore at (212) 355-4648.

What time period does the class action cover?

The class action covers from February 28, 2024, to February 25, 2025.

What is the focus of the investigation?

The investigation focuses on potential breaches of fiduciary duties by Geron's board.

Is there a cost for contacting the law firm?

There is no cost or obligation to contact Bragar Eagel & Squire, P.C.

Last updated: Oct 23, 2025